Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery

This publication has 31 references indexed in Scilit:

• Prevention of Venous Thromboembolism
  Chest, 2004
• A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism
  PharmacoEconomics, 2004
• Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture SurgeryA Multicenter, Randomized, Placebo-Controlled, Double-blind Study
  Archives of internal medicine (1960), 2003
• Estimating Hip Fracture Morbidity, Mortality and Costs
  Journal of the American Geriatrics Society, 2003
• Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
  PharmacoEconomics, 2003
• Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States
  Clinical Therapeutics, 2002
• Cost/Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Total Knee Replacement or Knee Arthroplasty
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
• The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With EnoxaparinA Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty
  Archives of internal medicine (1960), 1998
• Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
  American Journal of Health-System Pharmacy, 1997
• Epidemiology of Hip Fractures
  Epidemiologic Reviews, 1997